Prescient Therapeutics Ltd has released a press release.
PTX-200 AML Trial Progresses to Next Dose Level
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- June 2020 Quarterly Update and Appendix 4C
- 2 PTX Assets Chosen in Doherty Institute COVID-19 Program
- Trading Pause
- Reinstatement to Official Quotation
- PTX signs next-gen anti-cancer platform from Penn & Oxford
Later from Prescient Therapeutics
- PTX-100 progresses to next cohort in basket clinical study
- PTX Announces Cell Therapy Collaboration with Peter Mac
- Extension of Share Purchase Plan
- Successful SPP Closed Early
- Appendix 4E and 2020 Annual Report
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics